Commentary on sclerostin deficiency is linked to altered bone composition

Journal of Bone and Mineral Research

Volumn 29, Issue 10, 2014, Pages 2141-2143

  Eriksen, Erik Fink ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOGLYCAN; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; GLYCOPROTEIN; SOST PROTEIN, HUMAN; SOST PROTEIN, MOUSE;

ALBERS SCHOENBERG DISEASE; BONE MASS; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; HUMAN; NONHUMAN; NOTE; OSSIFICATION; OSTEOCYTE; OSTEOSCLEROSIS; PROTEIN DEFICIENCY; PYCNODYSOSTOSIS; SCLEROSTIN DEFICIENCY; ANIMAL; BONE DENSITY; DEFICIENCY; GENETIC MARKER;

ANIMALS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; GLYCOPROTEINS; HUMANS;

EID: 84907646278     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2346     Document Type: Note

References (35)

1. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250-61.
2. Chavassieux P, Seeman E, Delmas PD. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev. 2007;28(2):151-64.
3. Parfitt AM. Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone. 1992; 13(Suppl 2):S41-7.
4. van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26(12):2804-11.
5. Whyte MP. Genetic, developmental and dysplastic skeletal disorders. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research; 2003. p.449-66.
6. Hassler N, Roschger A, Gamsjaeger S, et al. Sclerostin deficiency is linked to altered bone composition. J Bone Miner Res. 2014;29:2144-51.
7. Beighton PH, Hamersma H, Brunkow ME. SOST-Related Sclerosing Bone Dysplasias. 2002 Jun 4 [updated 2013 Jan 10; cited 2014 Aug 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1228/.
8. Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab. 2003;88(12):5778-83.
9. Bollerslev J, Steiniche T, Melsen F, Mosekilde L. Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone. 1989;10(1):19-24.
10. Helfrich MH, Aronson DC, Everts V, et al. Morphologic features of bone in human osteopetrosis. Bone. 1991;12(6):411-9.
11. Fratzl-Zelman N, Valenta A, Roschger P, et al. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab. 2004;89(4):1538-47.
12. Keaveny TM, Hoffmann PF, Singh M, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008;23(12):1974-82.
13. Paschalis EP, Boskey AL, Kassem M, Eriksen EF. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res. 2003;18(6):955-9.
14. Paschalis EP, Glass EV, Donley DW, Eriksen EF. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab. 2005;90(8):4644-9.
15. Diez-Perez A, Guerri R, Nogues X, et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res. 2010;25(8):1877-85.
16. Hansma P, Turner P, Drake B, et al. The bone diagnostic instrument II: indentation distance increase. Rev Sci Instrum. 2008;79(6):064303.
17. Paschalis EP, DiCarlo E, Betts F, Sherman P, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human osteonal bone. Calcif Tissue Int. 1996;59(6):480-7.
18. Garnero P. The contribution of collagen crosslinks to bone strength. Bonekey Rep. 2012;1:182.
19. DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. 2010;340:b5463.
20. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21(2):195-214.
21. Oxlund H, Barckman M, Ortoft G, Andreassen TT. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone. 1995;17(4 Suppl):365S-71S.
22. Garnero P, Bauer DC, Mareau E, et al. Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res. 2008;23(9):1442-8.
23. Donnelly E, Chen DX, Boskey AL, Baker SP, van der Meulen MC. Contribution of mineral to bone structural behavior and tissue mechanical properties. Calcif Tissue Int. 2010;87(5):450-60.
24. Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone. Calcif Tissue Int. 1997;61(6):487-92.
25. Misof BM, Gamsjaeger S, Cohen A, et al. Bone material properties in premenopausal women with idiopathic osteoporosis. J Bone Miner Res. 2012;27(12):2551-61.
26. Boskey AL, Spevak L, Doty SB, Rosenberg L. Effects of bone CS-proteoglycans, DS-decorin, and DS-biglycan on hydroxyapatite formation in a gelatin gel. Calcif Tissue Int. 1997;61(4):298-305.
27. Mochida Y, Duarte WR, Tanzawa H, Paschalis EP, Yamauchi M. Decorin modulates matrix mineralization in vitro. Biochem Biophys Res Commun. 2003;305(1):6-9.
28. Bollerslev J, Marks SC Jr, Mosekilde L, Lian JB, Stein GS. Cortical bone osteocalcin content and matrix composition in autosomal dominant osteopetrosis type I. Eur J Endocrinol. 1994;130(6):592-4.
29. Semba I, Ishigami T, Sugihara K, Kitano M. Higher osteoclastic demineralization and highly mineralized cement lines with osteocalcin deposition in a mandibular cortical bone of autosomal dominant osteopetrosis type II: ultrastructural and undecalcified histological investigations. Bone. 2000;27(3):389-95.
30. Boskey AL. Marks SC Jr. Mineral and matrix alterations in the bones of incisors-absent (ia/ia) osteopetrotic rats. Calcified tissue international. 1985;37(3):287-92.
31. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948-59.
32. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-88.
33. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19-26.
34. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-20.
35. Ross RD, Edwards LH, Acerbo AS, et al. Bone matrix quality following sclerostin antibody treatment. J Bone Miner Res. 2014 Jul;29(7):1597-607.